sr141716 has been researched along with oxotremorine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kathmann, M; Schlicker, E; Weber, B | 1 |
| Buchalla, R; Jergas, B; Kurz, CM; Lutz, B; Redmer, A; Schlicker, E; Schulte, K; Steingrüber, N; Zimmer, A | 1 |
2 other study(ies) available for sr141716 and oxotremorine
| Article | Year |
|---|---|
Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice.
Topics: Acetylcholine; Animals; Benzoxazines; Brain; Calcium; Choline; Cyclohexanols; Dose-Response Relationship, Drug; Electric Stimulation; Hippocampus; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Morpholines; Naphthalenes; Oxotremorine; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Tritium | 2001 |
Cannabinoid CB1 receptor activation, pharmacological blockade, or genetic ablation affects the function of the muscarinic auto- and heteroreceptor.
Topics: Analgesics, Opioid; Animals; Arachidonic Acid; Arachidonic Acids; Cerebral Cortex; Cholinergic Neurons; Endocannabinoids; Enkephalin, D-Penicillamine (2,5)-; Glycerides; GTP-Binding Protein alpha Subunits; Hippocampus; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscarinic Agonists; Oxotremorine; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptors, Muscarinic; Receptors, Opioid, delta; Rimonabant; Synaptosomes; Vas Deferens | 2012 |